Abbott Laboratories
ABT
$109.61
$0.990.91%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.02% | 7.78% | 4.42% | 6.90% | 7.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.02% | 7.78% | 4.42% | 6.90% | 7.37% |
| Cost of Revenue | 9.70% | 9.44% | 0.68% | 8.02% | 5.45% |
| Gross Profit | 15.59% | 6.52% | 7.42% | 6.01% | 8.90% |
| SG&A Expenses | 31.27% | 22.89% | 7.41% | 5.18% | 5.29% |
| Depreciation & Amortization | 56.67% | 0.48% | -9.25% | -10.64% | -10.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.09% | 13.41% | 2.09% | 6.05% | 4.38% |
| Operating Income | -15.74% | -18.26% | 13.83% | 10.58% | 21.57% |
| Income Before Tax | -29.12% | -18.50% | 16.16% | 12.37% | 33.79% |
| Income Tax Expenses | 60.65% | -17.88% | 108.08% | 82.31% | 21.64% |
| Earnings from Continuing Operations | -47.84% | -18.72% | -80.76% | -0.12% | 36.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.84% | -18.72% | -80.76% | -0.12% | 36.64% |
| EBIT | -15.74% | -18.26% | 13.83% | 10.58% | 21.57% |
| EBITDA | -2.12% | -11.13% | 9.59% | 7.19% | 13.85% |
| EPS Basic | -47.75% | -18.86% | -81.02% | -0.27% | 36.60% |
| Normalized Basic EPS | -28.99% | -18.66% | 12.72% | 12.19% | 22.82% |
| EPS Diluted | -47.52% | -19.74% | -80.95% | 0.00% | 36.49% |
| Normalized Diluted EPS | -28.79% | -18.49% | 12.72% | 12.27% | 22.88% |
| Average Basic Shares Outstanding | -0.17% | 0.19% | 0.06% | 0.15% | 0.02% |
| Average Diluted Shares Outstanding | -0.45% | -0.01% | 0.06% | 0.10% | -0.02% |
| Dividend Per Share | 6.78% | 6.78% | 6.78% | 7.27% | 7.27% |
| Payout Ratio | 1.05% | 0.32% | 4.59% | 0.08% | -0.22% |